| Accession |
PRJCA016229 |
| Title |
An open-label, single-arm, multi-center, phase II clinical trial of PD-1 antibody SHR-1210 in patients with advanced/metastatic non-small cell lung cancer (NSCLC) |
| Relevance |
Medical |
| Data types |
clinical,image,Metabolic,Biomarker data
|
| Organisms |
Homo sapiens
|
| Description |
To evaluate the efficacy of anti-PD-1 antibody SHR-1210 on Objective response rate (ORR) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) with different PD-L1 expression levels after failure of previous systemic therapy |
| Sample scope |
Multiisolate |
| Release date |
2023-04-16 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| NA
|
|
NA
|
|
|
|
| Submitter |
wanqiu
liang (wanqiu.liang@hengrui.com)
|
| Organization |
Jiangsu Hengrui Pharmaceutical Co. LTD |
| Submission date |
2023-04-13 |
